Tag Archives: NASDAQ:RVNC

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (NASDAQ: RVNC) and BioMarin (NASDAQ: BMRN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (NASDAQ: RVNC) and BioMarin (NASDAQ: BMRN). Revance Therapeutics (NASDAQ: RVNC) In a report released today, Rohit Vanjani from Guggenheim maintained a

Cantor Fitzgerald Reaffirms Their Buy Rating on Revance Therapeutics

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $29.85. Chen commented: “Today, RVNC announced four new senior roles for its

A Director at Revance Therapeutics (NASDAQ: RVNC) is Buying Shares

Yesterday, a Director at Revance Therapeutics (NASDAQ: RVNC), Philip Vickers, bought shares of RVNC for $98.39K. Following this transaction Philip Vickers’ holding in the company was increased by 150% to a total of $190.7K. In addition to Philip Vickers, 2

The CFO, CBO & Secretary of Revance Therapeutics (NASDAQ: RVNC) is Buying Shares

Yesterday, the CFO, CBO & Secretary of Revance Therapeutics (NASDAQ: RVNC), Lauren Silvernail, bought shares of RVNC for $225K. Following this transaction Lauren Silvernail’s holding in the company was increased by 35.46% to a total of $2.27 million. The company

Piper Jaffray Keeps Their Buy Rating on Revance Therapeutics

In a report released today, David Amsellem from Piper Jaffray reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC), with a price target of $48. The company’s shares opened today at $29.25. According to TipRanks.com, Amsellem is ranked 0 out

Guggenheim Remains a Buy on Revance Therapeutics

In a report released yesterday, Rohit Vanjani from Guggenheim reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC), with a price target of $44. The company’s shares closed yesterday at $35.90, close to its 52-week high of $37.45. According to